Gordon, LeslieKieran, Mark WKleinman, MonicaMisteli, Tom2016-08-092016Gordon, Leslie B, Mark W Kieran, Monica E Kleinman, and Tom Misteli. 2016. “The decision‐making process and criteria in selecting candidate drugs for progeria clinical trials.” EMBO Molecular Medicine 8 (7): 685-687. doi:10.15252/emmm.201606280. http://dx.doi.org/10.15252/emmm.201606280.1757-4676http://nrs.harvard.edu/urn-3:HUL.InstRepos:27822258Hutchinson–Gilford progeria syndrome (progeria) is an extremely rare premature aging disease with a population prevalence of 1 in 20 million. Nevertheless, propelled by the discovery of a causal mutation in the lamin A/C gene (LMNA) (De Sandre‐Giovannoli et al, 2003; Eriksson et al, 2003) and strong patient advocacy (Gordon & Gordon, 2014), progeria has rapidly become a vibrant field of study, attracting a wide range of researchers from basic cell biologists to clinicians.en-USCommentaryGenetics, Gene Therapy & Genetic DiseasePharmacology & Drug DiscoveryJournal Article2016-08-0910.15252/emmm.201606280